Cumberland Pharmaceuticals (CPIX) Tops Q4 EPS by 2c, Revenues Beat

Cumberland Pharmaceuticals (NASDAQ: CPIX) reported Q4 EPS of $0.01, $0.02 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $10.26 million versus the consensus estimate of $9.78 million.

"We are grateful that Cumberland was able to successfully manage through the pandemic during 2020, in spite of the significant market headwinds and other challenges we encountered," said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals. "Our facilities remained open, our operations continued, and our organization remained intact." He continued, "I would like to acknowledge and thank my colleagues for their continued dedication during such trying times for many. Together, we remain focused on our mission of advancing patient care through the delivery of high-quality medicines."

For earnings history and earnings-related data on Cumberland Pharmaceuticals (CPIX) click here.

You May Also Be Interested In

• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• Arvinas CMO to depart in July as company begins search
• NVE Corporation names new CEO and expands board to seven members